Trametinib as a single agent in BRAF mutated NSCLC. The MEK inhibitor, selumetanib has been shown to downregulate ERK signaling in preclinical lung models with KRAS mutated NSCLC, but a similar effect has not been demonstrated in BRAF mutated NSCLC [25]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.